BioXcel Therapeutics, Inc. (BTAI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

24.50+0.27 (+1.11%)

As of 10:06AM EDT. Market open.

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	24.23
Open	24.27
Bid	24.12 x 800
Ask	24.37 x 800
Day's Range	24.11 - 24.80
52 Week Range	23.79 - 67.74
Volume	69,573
Avg. Volume	393,744

Market Cap	680.782M
Beta (5Y Monthly)	1.07
PE Ratio (TTM)	N/A
EPS (TTM)	-4.06
Earnings Date	Aug 12, 2021 - Aug 16, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	100.45

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

TipRanks
3 “Strong Buy” Stocks Trading at Rock-Bottom Prices
When a stock’s price falls into the doldrums, it’s tempting to just avoid those shares. After all, rock bottom prices usually happen for a reason, and those reasons are usually not good for the stock’s prospects. But there are times – more frequent than most would guess – that this common wisdom runs counter to the facts. Because the fact is, many fundamentally sound stocks can and do see periods of falling share price. Maybe there was change in company leadership, or a hyped product failed to m
- Patients Rate their Clinical Trial Experience Positively, but Trial Locations Still Pose Barriers to Enrollment
  GlobeNewswire
- Ultragenyx Receives Orphan Drug Designation from FDA and European Commission for UX053, an Investigational mRNA-therapy for the Treatment of Glycogen Storage Disease Type III
  GlobeNewswire
GlobeNewswire
BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive Officer of BioXcel, will participate in the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 9:30 a.m. Eastern Time. To access the live webcast of BioXcel’s presentation, please visit the “Events” page within the News & Media section of the Company's website at www.bioxce
Insider Monkey
Hedge Funds Are Dumping BioXcel Therapeutics, Inc. (BTAI)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]